Pfizer Inc. PFE shares are trading flat during Wednesday’s premarket session as traders weigh mixed Phase 3 trial headlines ...

Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Pfizer shares have gained ground since a report over the weekend said that activist investor ...

Pfizer's business may be in better shape than investors think.

Pfizer (PFE) stock drops 3% as CFO Dave Denton reveals August exit. Cecile Guegan appointed interim CFO while company ...

Pfizer’s PFE $13.7 billion in revenue (an 8% decline) and adjusted diluted EPS of $0.92 (12% growth) allowed the firm to maintain its full-year guidance of $61 billion-$64 billion in revenue and $2.80 ...

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its fourth-quarter results. Analyst firm Edward Jones expects Pfizer’s future growth to ...

Pfizer navigates a changing pharmaceutical landscape through pipeline expansion, innovation, and portfolio transformation as ...

By 2029, Pfizer CEO Albert Bourla believes the company may return to high-single-digit growth. Recent settlements have pushed back the patent cliff for a key drug, giving the company more breathing ...

Pfizer gains healthcare attention as expanded hemophilia approval broadens treatment use while organizational change shapes ...

New launches and acquired drugs offset COVID product declines Vyndamax patent extension and favorable EU court ruling expected to boost post-2028 growth First-quarter revenue and profit beat estimates ...